MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 08-13-2024
TRACON Pharmaceuticals Cash and Cash Equivalents 2011-2026 | TCON
Annual Cash and Cash Equivalents TRACON Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.56 M | 17.4 M | 24.1 M | 32.1 M | 16.4 M | 25.1 M | 29.5 M | 35.7 M | 41.4 M | 35 M | 2.28 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 41.4 M | 2.28 M | 24.3 M |
Quarterly Cash and Cash Equivalents TRACON Pharmaceuticals
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.27 M | 7.89 M | 8.56 M | 7.76 M | 1.87 M | 6.68 M | 17.4 M | 17.2 M | 13.6 M | 16.6 M | 24.1 M | 29.9 M | 25.6 M | 26.4 M | 32.1 M | 32.1 M | 32.1 M | 32.1 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 25.1 M | 25.1 M | 25.1 M | 25.1 M | 29.5 M | 29.5 M | 29.5 M | 29.5 M | 35.7 M | 35.7 M | 35.7 M | 35.7 M | 41.4 M | 41.4 M | 41.4 M | 41.4 M | 35 M | 35 M | 35 M | 35 M | 2.28 M | - | - | - | 2.46 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 41.4 M | 1.87 M | 24.4 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
BioNTech SE
BNTX
|
7.68 B | $ 91.21 | 0.03 % | $ 27.2 B | Germany |
 |
Alnylam Pharmaceuticals
ALNY
|
1.66 B | $ 330.79 | 3.74 % | $ 43.3 B |  USA |
 |
BioLineRx Ltd.
BLRX
|
10.4 M | $ 2.34 | 5.72 % | $ 908 M |  Israel |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B |  France |
 |
Cerus Corporation
CERS
|
20 M | $ 1.87 | 0.27 % | $ 356 M | USA |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | France |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
3.33 M | $ 0.46 | -13.08 % | $ 5.27 M | Israel |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | USA |
 |
CNS Pharmaceuticals
CNSP
|
7.2 M | $ 2.29 | 1.11 % | $ 1.02 M | USA |
 |
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
103 M | $ 2.97 | -0.67 % | $ 253 M | USA |
 |
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
34 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
709 M | $ 24.91 | 0.89 % | $ 3.05 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
30 M | - | 3.16 % | $ 1.9 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
28.5 M | $ 10.08 | -0.88 % | $ 134 M | USA |
 |
Cardiff Oncology
CRDF
|
17.5 M | $ 1.59 | 0.32 % | $ 106 M | USA |
 |
Alpine Immune Sciences
ALPN
|
13.4 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
3.22 M | - | 10.36 % | $ 9.8 M | USA |
 |
Curis
CRIS
|
5.06 M | $ 0.53 | -3.58 % | $ 6.98 M | USA |
 |
Aquestive Therapeutics
AQST
|
121 M | $ 4.1 | -0.85 % | $ 438 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
102 M | $ 37.76 | 1.42 % | $ 3.55 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
348 M | $ 49.35 | -0.32 % | $ 4.44 B |  Schweiz |
 |
CytomX Therapeutics
CTMX
|
12.7 M | $ 4.35 | -4.61 % | $ 600 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
3.25 M | $ 0.88 | 2.44 % | $ 5.92 M | USA |
 |
Cue Biopharma
CUE
|
27.1 M | $ 0.17 | -6.06 % | $ 16.1 M | USA |
 |
Aravive
ARAV
|
53.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
231 M | $ 8.24 | 2.55 % | $ 226 M | Israel |
 |
Cyclerion Therapeutics
CYCN
|
3.23 M | $ 4.13 | -32.85 % | $ 10.4 M | USA |
 |
Aptose Biosciences
APTO
|
935 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | USA |
 |
Daré Bioscience
DARE
|
24.7 M | $ 1.77 | 1.75 % | $ 19.8 M | USA |
 |
DBV Technologies S.A.
DBVT
|
194 M | $ 20.47 | -2.8 % | $ 2.86 B | France |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
5.71 B | - | - | $ 96.9 B | Britain |
 |
Celldex Therapeutics
CLDX
|
28.9 M | $ 31.46 | 1.29 % | $ 2.09 B | USA |
 |
Avenue Therapeutics
ATXI
|
2.86 M | - | -52.27 % | $ 4.45 M | USA |